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Background: Candidiasis is the commonest opportunistic fungal infection in patients infected with human
immunodeficiency virus (HIV). CD4 lymphocyte counts have been found to be a marker of HIV disease
progression.
Aim: This study focused on determining the spectrum of Candida isolates in urine, stool, and oral specimens
among HIV patients in a tertiary hospital.
Methods: A total of 300 subjects comprising of 200 HIV patients and 100 non-HIV subjects were used for this
study. Three samples (urine, stool, and oral swab) were collected from each subject. Each specimen was
processed using standard microbiological techniques and emergent Candida isolates were identified with
CHROMagarTM Candida and sugar fermentation tests.
Results: The overall prevalence of Candida colonisation among HIV patients was 52.5%. HAART-naive
patients had a significantly higher prevalence (OR3.65; 95% CI2.036.56; pB0.0001) than their
counterpart on highly active antiretroviral therapy (HAART) (OR1.99; 95% CI1.133.50; p0.0232).
Female gender was a significant risk factor for acquiring Candida infection (OR3.40; 95% CI1.1410.13;
p0.0289). The effect of age on prevalence of candidiasis was observed among HIV patients on HAART
(p0.0161). A CD4 count B200 cells/ml was a significant risk factor for acquiring candidal infection only
among HAART-naive patients (OR4.37; 95% CI1.6011.95; p0.0042). The five species of Candida
recovered from this study were C. albicans, C. krusei, C. parapsilosis, C. tropicalis, and C. glabrata.
Conclusion: There is a significant relationship between antiretroviral therapy, CD4 counts, and the
prevalence of candidiasis.
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T
he human immunodeficiency virus (HIV) has
emerged as a global disaster (1). HIV/AIDS con-
tinues to spread globally and remains a worldwide
pandemic affecting about 40 million people (2). The
pandemic is the leading cause of death in sub-Saharan
Africa and the fourth leading cause of mortality world-
wide, with over 95% of these deaths occurring among
young adults in the developing world (3, 4). AIDS is
caused by HIV and is characterised by progressive
damage to the immune system, which opens the door to
different opportunistic infections (5), including fungal
infections. The commonly encountered fungal infections
in HIV-positive patients are candidiasis, cryptococcosis,
histoplasmosis, pneumocystosis, coccidioidomycosis, and
penicilliosis (1, 6, 7).
The effect of fungal diseases among patients with HIV
infection was recognised in the early days of the AIDS
epidemic. Fungal infections were reported in many of
the first patients described with a new acquired cellular
immunodeficiency in 1981 (8, 9). The risk of fungal
infection depends primarily on these factors: the severity
of impairment of cell-mediated immunity; the risk of
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exposure; recent or current use of an antifungal medica-
tion; and neutropenia that relates primarily to invasive
candidiasis (6).
Infections with Candida appear when the CD4 count
is 200500 cells/ml and may be the first indication of
immunodeficiency (10). The factors contributing to the
pathogenesis of Candida and its progression in HIV
patients are poorly understood, but they may include
biofilm production, an interrelationship between HIV
and Candida, and/or dysfunction in the local immunity
super-imposed on weakened cell-mediated immunity and
depletion of CD4 T cells (1113).
Highly active antiretroviral therapy (HAART) has
generally been taken as the gold standard in the manage-
ment of HIV patients (14). The use of HAART results in
improved quality of life for HIV patients (6) as well as
near normal turnover of both CD4 and CD8 T-cell
populations (1517). Therefore, it is expected that in the
era of HAART, immunity of HIV patients will be
improved and opportunistic infections reduced. However,
oropharyngeal and oesophageal candidiasis continues to
afflict HIV-infected individuals in the HAART (1822).
There are few or no reported studies on Candida infection
among HIV patients in Benin City, Nigeria. This study
was conducted against this background.
Materials and methods
Study area
The study was carried out in the University of Benin
Teaching Hospital, Benin City, Nigeria. It is located in
the SouthSouth geopolitical zone of Nigeria. It serves as
a referral hospital for about six to ten states in Nigeria.
It is a centre for the Institute of Human Virology,
Nigeria, and US President’s Emergency Plan for AIDS
Relief (PEPFAR) HIV/AIDS interventions in the zone.
Study population
The study included 300 subjects consisting of 200 HIV
patients and 100 (42 males and 58 females) apparently
healthy age-matched non-HIV subjects. The patients
consisted of 100 HAART-naive patients (31 males and
69 females) and 100 HIV patients on HAART for
36 months (22 males and 78 females). The HAART
regimen included zidovudine, stavudine, and nevirapine.
The HIV patients were out-patients and asymptomatic.
Informed consent was obtained from all subjects prior
to specimen collection. The Ethical Committee of the
University of Benin Teaching Hospital approved the
protocol for this study.
Specimen collection and processing
Venous blood samples (5 ml) were collected into ethylene
diamine tetraacetic acid (EDTA) containers and mixed.
Stool specimens were collected in sterile wide-mouthed
containers and clean-catch mid-stream urine was col-
lected in sterile universal containers containing a few
crystals of boric acid as preservative. Oral swabs were
collected with sterile swab sticks.
The blood specimens were used for CD4 counts using
flow cytometry (Partec, Germany) following the manu-
facturer’s instructions.
Stool specimens were processed as previously described
(23). Briefly, 1 g of faeces was emulsified in 10 ml
of sterile water. A loopful (0.001 ml) of this was streaked
on the surface of two sets of Sabouraud’s dextrose
agar (SDA) and brain heart infusion agar (BHIA),
each containing 5 mg/ml of gentamicin. The plates were
incubated at 378C for 2448 h. The counts were expressed
in colony forming units per ml (cfu/ml). A count of ]105
cfu/ml was considered indicative of Candida colonisation.
A loopful (0.001 ml) of well-mixed un-centrifuged urine
was streaked onto the surface of SDA and BHIA. The
plates were incubated aerobically at 378C for 2448 h
and counts were expressed in cfu/ml. A count of ]105
cfu/ml was considered indicative of asymptomatic urinary
candiduria. The urine specimens were centrifuged at
2,000 g for 5 min. The supernatant was discarded, and a
drop of the deposit was examined microscopically at high
magnification for pus cells. Urinary candidiasis was diag-
nosed if the yeast count was significant in an individual.
Oral swab was inoculated on SDA and BHIA, each
containing 5 mg/ml gentamicin, and incubated at 378C
for 2448 h. Emergent yeast colonies were stored for
identification.
All Candida isolates were identified with CHROMa-
garTM Candida (Paris, France) and sugar fermentation test
as previously described (24, 25).
Results
HIV patients were at higher risk of acquiring Candida
infection (HIV vs. non-HIV; OR2.58, 95% CI1.16
4.30, p0.0002). However, considering the prevalence of
Candida in relation to HIV status (HAART-naive or on
HAART) and that of non-HIV subjects, only HAART-
naive HIV patients had significantly higher prevalence
of Candida colonisation (HAART-naive vs. control;
OR3.65, 95% CI2.036.56, pB0.0001). In a similar
vein, HAART-naive HIV patients were at higher risk of
acquiring Candida colonisation than their counterparts
on HAART (OR9.99, 95% CI1.1393.50, p0.0232;
Table 1). The effect of gender on the prevalence of
Candida colonisation among HIV and non-HIV subjects
was noticed only among HIV patients on HAART,
where female gender was at significant risk of acquiring
Candida colonisation (OR3.40, 95% CI1.1410.13,
p0.0289; Table 1).
The prevalence of Candida colonisation increased with
age. However, this increase was only statistically signifi-
cant (p0.0161) among HIV patients on HAART, where
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the age group of 6170 years had the highest prevalence
(Table 2).
A CD4 count B200 cells/ml was a significant risk factor
for acquiring candidiasis only among HAART-naive HIV
patients (OR4.37, 95% CI1.6011.95, p0.0042;
Table 3).
Five species of Candida were recovered. C. albicans
was the most prevalent followed by C. krusei and C.
parapsilosis, while C. tropicalis and C. glabrata were the
least prevalent and were recovered only from stool
specimens. C. glabrata was recovered only from HIV
patients on HAART, while C. albicans was the only
Candida species recovered from the oral cavity of HIV
patients on HAART (Table 4).
Discussion
The severity of Candida infections increases with the
number and severity of predisposing factors, such as
immunodeficiency (6). Even in the HAART era, orophar-
yngeal and oesophageal candidiasis are still rife (22).
Although reports of oral candidiasis abound, there is no
report from Benin City. Against this background, this
study focused on determining the spectrum of Candida
isolates from urine, stool, and oral specimens among HIV
patients in a tertiary hospital.
HIV status is a risk factor for acquiring Candida
colonisation. This agrees with previous reports (1).
However, this effect was observed only among HAART-
naive HIV patients. HAART has been reported to
improve immunity (14) and immunosuppression is among
the factors that predispose to opportunistic Candida
infections (1). This may explain the result in this study.
Table 1. Prevalence of Candida colonisation among HIV and non-HIV subjects
Male Female Total
Status No. of sampled No. of infected (%) No. of sampled No. of infected (%) No. of sampled No. of infected (%)
Non-HIV 42 14 (33.3) 58 16 (27.6) 100 30 (30.0)
Mixed infection 42 0 (0) 58 1 (1.72) 100 1 (1.0)
HIV patients
HAART naive2 31 17 (54.8) 69 44 (63.7) 100 61 (61.0)
Mixed infection 31 5 (16.3) 69 10 (14.49) 100 15 (15.0)
On HAART1,3 22 5 (22.7) 78 39 (50.0) 100 44 (44.0)
Mixed infection 22 0 (0) 78 3 (3.85) 100 3 (3.0)
HIV versus non-HIV: OR2.58; 95% CI1.1604.30; p0.0002.
1On HAART versus control: OR1.83; 95% CI1.023.28; p0.0569.
2HAART naive versus control: OR3.65; 95% CI2.036.56; pB0.0001.
3HAART naive versus on HAART: OR1.99, 95% CI1.133.50; p0.0235.
Table 2. Prevalence of Candida colonisation among HIV








2130 13 9 (69.2)
3140 49 32 (65.3)
4250 33 17 (51.5)
5160 4 3 (75.0)
6170 1 0 (0.0)
Total 100 61 (61.0)
On HAART 0.0161
2130 15 7 (46.7)
3140 44 12 (27.3)
4150 28 17 (60.7)
5160 10 05 (50.0)
6170 3 03 (100.0)
Total 100 44 (44.0)
Non-HIV 0.1592
2130 41 10 (24.4)
3140 35 9 (25.7)
4150 16 5 (31.3)
5160 2 2 (100.0)
6170 6 4 (66.7)
Total 100 30 (30.0)









(%) OR 95% CI p
HAART-naı̈ve 0.0055
B200 33 27 (81.8) 4.37 1.6011.95
]200 67 34 (50.7) 0.23 0.0840.62
On HAART 1.000
B200 11 5 (45.5) 1.09 0.303.76
]200 89 39 (43.6) 0.94 0.273.30
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The effect of age on the prevalence of Candida
colonisation was significant only among HIV patients
on HAART, with age group 6170 years having the
highest prevalence. The reason for this significant effect
in the HAART group is unclear. However, the elderly are
known to have weaker immunity (25). The observed
higher prevalence of Candida colonisation among the
elderly is consistent with a recent report (13). The effect
of gender on prevalence of Candida colonisation was
observed only among female HIV patients on HAART.
This may be a result of proximity of the anal region to the
urinary tract in females and to hormonal imbalance.
A CD4 countB200 cells/ml was a significant risk factor
for acquiring candidiasis among HAART-naive HIV
patients (Table 3). This finding is supported by earlier
observations of Schoots et al. (26) and Njunda et al. (22),
both of whom reported a significant relationship between
low CD4 counts (B200 cells/ml) and candidiasis. This was
expected, as immune suppression is a hallmark of HIV
infection (27).
Irrespective of HIV status and type of specimen
processed, C. albicans was the most predominant species
recovered in this study. This is in agreement with previous
studies (19, 22, 2831). Other Candida species recovered
in this study were C. krusei, C. parapsilosis, C. glabrata
and C. tropicalis. These species of Candida were pre-
viously reported among HIV patients (13, 19). It is
important to note that only C. krusei and C. glabrata
were recovered from non-HIV subjects in addition to
C. albicans, and they were recovered from oral swab and
stool specimens, respectively. This may indicate that other
species of Candida isolated are associated with immuno-
suppression. It has been reported that Candida infections
among HIV patients are refractory to antifungal agents
(22), thus making this infection life-threatening among
HIV patients.
Conclusion
To sum up, candidiasis remains an important opportun-
istic infection among HIV patients. Measures to reduce
its prevalence, such as prompt treatment with appropriate
antifungals, strict compliance with HAART regimen, and
reducing practices that promote yeast overgrowth, are
advocated.
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